In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats - PubMed (original) (raw)
In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats
L Rossetti et al. J Clin Invest. 1995 Jul.
Abstract
To test the hypothesis that increased flux through the hexosamine biosynthetic pathway can induce insulin resistance in skeletal muscle in vivo, we monitored glucose uptake, glycolysis, and glycogen synthesis during insulin clamp studies in 6-h fasted conscious rats in the presence of a sustained (7-h) increase in glucosamine (GlcN) availability. Euglycemic (approximately 7 mM) insulin (approximately 2,500 pM) clamps with saline or GlcN infusions were performed in control (CON; plasma glucose [PG] = 7.4 +/- 0.2 mM), diabetic (D; PG = 19.7 +/- 1.1), and phlorizin-treated (3-wk) diabetic rats (D + PHL; PG = 7.6 +/- 0.9). 7-h euglycemic hyperinsulinemia with saline did not significantly decrease Rd (360-420 min = 39.2 +/- 3.6 vs. 60-120 min = 42.2 +/- 3.7 mg/kg.min; P = NS). GlcN infusion raised plasma GlcN concentrations to approximately 1.2 mM and increased muscle and liver UDP-GlcNAc levels by 4-5-fold in all groups. GlcN markedly decreased Rd in CON (360-420 min = 30.4 +/- 1.3 vs. 60-120 min = 44.1 +/- 3.5 mg/kg.min; P < 0.01) and D + PHL (360-420 min = 29.4 +/- 2.5 vs. 60-120 min = 43.8 +/- 2.9 mg/kg.min; P < 0.01), but not in D (5-7 h = 21.5 +/- 0.8 vs. 0-2 h = 24.3 +/- 1.1 mg/kg.min; P = NS). Thus, increased GlcN availability induces severe skeletal muscle insulin resistance in normoglycemic but not in chronically hyperglycemic rats. The lack of additive effects of GlcN and chronic hyperglycemia (experimental diabetes) provides support for the hypothesis that increased flux through the GlcN pathway in skeletal muscle may play an important role in glucose-induced insulin resistance in vivo.
Similar articles
- Increased hexosamine availability similarly impairs the action of insulin and IGF-1 on glucose disposal.
Hawkins M, Barzilai N, Chen W, Angelov I, Hu M, Cohen P, Rossetti L. Hawkins M, et al. Diabetes. 1996 Dec;45(12):1734-43. doi: 10.2337/diab.45.12.1734. Diabetes. 1996. PMID: 8922359 - Role of the glucosamine pathway in fat-induced insulin resistance.
Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rossetti L. Hawkins M, et al. J Clin Invest. 1997 May 1;99(9):2173-82. doi: 10.1172/JCI119390. J Clin Invest. 1997. PMID: 9151789 Free PMC article. - Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance in multiple insulin sensitive tissues.
Virkamäki A, Daniels MC, Hämäläinen S, Utriainen T, McClain D, Yki-Järvinen H. Virkamäki A, et al. Endocrinology. 1997 Jun;138(6):2501-7. doi: 10.1210/endo.138.6.5172. Endocrinology. 1997. PMID: 9165041 - Hexokinase-2-Linked Glycolytic Overload and Unscheduled Glycolysis-Driver of Insulin Resistance and Development of Vascular Complications of Diabetes.
Rabbani N, Xue M, Thornalley PJ. Rabbani N, et al. Int J Mol Sci. 2022 Feb 16;23(4):2165. doi: 10.3390/ijms23042165. Int J Mol Sci. 2022. PMID: 35216280 Free PMC article. Review. - cypate-d: -(+)-glucosamine (cyp-GlcN), and d: -(+)-glucosamine-cypate-d: -(+)-glucosamine (cyp-2GlcN).
Chopra A. Chopra A. 2012 Aug 8 [updated 2012 Sep 13]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2012 Aug 8 [updated 2012 Sep 13]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 22993875 Free Books & Documents. Review.
Cited by
- The Hexosamine Biosynthesis Pathway: Regulation and Function.
Paneque A, Fortus H, Zheng J, Werlen G, Jacinto E. Paneque A, et al. Genes (Basel). 2023 Apr 18;14(4):933. doi: 10.3390/genes14040933. Genes (Basel). 2023. PMID: 37107691 Free PMC article. Review. - Hexosamine pathway activation improves memory but does not extend lifespan in mice.
Allmeroth K, Hartman MD, Purrio M, Mesaros A, Denzel MS. Allmeroth K, et al. Aging Cell. 2022 Oct;21(10):e13711. doi: 10.1111/acel.13711. Epub 2022 Sep 19. Aging Cell. 2022. PMID: 36124412 Free PMC article. - Posttranslational modifications in diabetes: Mechanisms and functions.
Hu A, Zou H, Chen B, Zhong J. Hu A, et al. Rev Endocr Metab Disord. 2022 Oct;23(5):1011-1033. doi: 10.1007/s11154-022-09740-x. Epub 2022 Jun 13. Rev Endocr Metab Disord. 2022. PMID: 35697961 Review. - 2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint.
Zhang Z, Huang C, Cao Y, Mu R, Zhang MC, Xing D, Fan D, Ding Y, Guo J, Hou Y, Jianhao L, Veronese N, Reginster JY, Bruyere O, Cavalier E, Zhang H. Zhang Z, et al. Aging Clin Exp Res. 2021 Aug;33(8):2141-2147. doi: 10.1007/s40520-021-01906-y. Epub 2021 Jun 29. Aging Clin Exp Res. 2021. PMID: 34189714 Free PMC article. Review. - NGBR is required to ameliorate type 2 diabetes in mice by enhancing insulin sensitivity.
Chen Y, Hu W, Li Q, Zhao S, Zhao D, Zhang S, Wei Z, Yang X, Chen Y, Li X, Liao C, Han J, Miao QR, Duan Y. Chen Y, et al. J Biol Chem. 2021 Jan-Jun;296:100624. doi: 10.1016/j.jbc.2021.100624. Epub 2021 Apr 2. J Biol Chem. 2021. PMID: 33812996 Free PMC article.
References
- Diabetes. 1992 May;41(5):571-80 - PubMed
- Am J Physiol. 1992 Apr;262(4 Pt 1):E440-6 - PubMed
- Biochem J. 1992 Jun 1;284 ( Pt 2):341-8 - PubMed
- Diabetes. 1993 Sep;42(9):1289-96 - PubMed
- Diabetes. 1993 Sep;42(9):1333-46 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous